Brind.

Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.

2 reports, 1 independent Updated Aug 19

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.

Who's involved

What this event is mainly about

Altimmune, Inc.FDA World Health Organization

Keep exploring

The entities involved

Altimmune, Inc.
American biopharmaceutical company
- X4 Pharmaceuticals and Altimmune, Inc. are small-cap healthcare companies trading on the Nasdaq stock exchange.Thu 14:20
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
World Health Organization
United Nations agency concerned with international public health
- The U.S. ordered its withdrawal from the World Health Organization amid global health initiative impacts.Mon 11:20
- The Ebola outbreak in the DRC is spreading to Uganda, with new cases reported in Ituri province.Mon 05:14

Related events

FDA granted Fast Track designation to NRX-100 on September 4, 2025.Jun 7

Coverage

Newest first; wire copies grouped

Aug 19GlobeNewswireAltimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of p
Jun 26Unknown outlet